XM does not provide services to residents of the United States of America.
A
A

Atos

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Eviden Wins 4-Year Multi-Million Euro Contract On Berzelius Supercomputer

BRIEF-Eviden Wins 4-Year Multi-Million Euro Contract On Berzelius Supercomputer Sept 17 (Reuters) - Atos SE ATOS.PA : EVIDEN HAS BEEN AWARDED A 4-YEAR MULTI-MILLION EURO CONTRACT TO BOOST PERFORMANCE OF BERZELIUS SUPERCOMPUTER Source text: tinyurl.com/2blkdqdc Further company coverage: ATOS.PA (Gdansk Newsroom)
A

Tepid start in store but STOXX remains near record

LIVE MARKETS-Tepid start in store but STOXX remains near record Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com TEPID START IN STORE BUT STOXX STILL NEAR RECORD European stocks are heading for a mixed start to Monday, as traders gear up for the first week of the month which will wrap up with a hotly anticipated U.S.
A
N
R
S
E
F
U
G

France's Atos cuts financial targets but says restructuring still on track

UPDATE 1-France's Atos cuts financial targets but says restructuring still on track Adds details and background from paragraph 3 By Tassilo Hummel PARIS, Sept 2 (Reuters) - French IT firm Atos ATOS.PA on Monday said it would have less cash at hand over the next few years as sales are being dragged down by a weaker business environment, but added this would not impact the key terms of its financial restructuring plan.
A

French IT group Atos cuts its sales and cash flow targets

French IT group Atos cuts its sales and cash flow targets PARIS, Sept 2 (Reuters) - French IT firm Atos ATOS.PA on Monday said it would have less cash at hand over the next few years as sales are being dragged down by a weaker business environment, but added this would not impact the key terms of its financial restructuring plan. Atos now sees a full-year 2024 group revenue of 9.7 billion euros ($10.72 billion), down from 9.8 billion euros previously estimated.
A

Cognizant sues software rival Infosys over trade secrets

UPDATE 1-Cognizant sues software rival Infosys over trade secrets Adds Infosys response in paragraph 3 By Blake Brittain Aug 23 (Reuters) - Software provider Cognizant TriZetto AXPAST.UL sued Indian tech company Infosys INFY.NS in Texas federal court on Friday, accusing Infosys of stealing trade secrets related to its healthcare insurance software.
A
C
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.